Polatuzumab Vedotin Approved for Previously Untreated Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma

The FDA has approved polatuzumab vedotin-piiq (Polivy®, Genentech, Inc.) plus R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) for adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL); including those who have an International Prognostic Index (IPI) score of 2 or greater. Why it matters: "Although most patients (depending on prognostic factors) can be cured with R-CHOP (rituximab, cyclo...

Continue reading

Axicabtagene Ciloleucel Approved for Second-Line Treatment of Large B-Cell Lymphoma

The FDA has approved axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for treatment of adult patients with large B-cell lymphoma (LBCL). Axicabtagene ciloleucel, also known as axi-cel, is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. It is indicated as a second-line treatment for patients who have already undergone first-line chemoimmunotherapy with no response or who have experienced relapse within 12 months of first-line chemoimmunotherapy. It is noted that axic...

Continue reading

Copyright © Oncology Data Advisor. All rights reserved.